% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wisch:281816,
      author       = {Wisch, Julie K and McKay, Nicole S and Zammit, Matthew and
                      Christian, Bradley T and Schultz, Stephanie A and Millar,
                      Peter R and Ryan, Natalie S and Cash, David M and Belder,
                      Christopher R S and Chrem, Patricio and Cruchaga, Carlos and
                      Ibanez, Laura and Jucker, Mathias and Yakushev, Igor and
                      Day, Gregory S and Murphy, Mei and Llibre-Guerra, Jorge and
                      Aguillon, David and Roh, Jee Hoon and Xiong, Chengjie and
                      Wang, Guoqiao and Li, Yan and Schindler, Suzanne E and Jack,
                      Cliff and McDade, Eric and Bateman, Randall J and Benzinger,
                      Tammie L S and Ances, Beau M and Betthauser, Tobey and
                      Gordon, Brian},
      collaboration = {Networ, Dominantly Inherited Alzheimer},
      title        = {{C}omparison of amyloid chronicity and {EYO} in autosomal
                      dominant {A}lzheimer's disease.},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {10},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-01198},
      pages        = {e70812},
      year         = {2025},
      abstract     = {Preclinical Alzheimer's disease (AD) can be described
                      relative to biomarker positivity onset time.We estimated
                      time from amyloid positivity (A+) using sampled iterative
                      local approximation (SILA) in a longitudinal autosomal
                      dominant AD (ADAD) sample (N = 379) with amyloid positron
                      emission tomography. We compared (1) predicted age at A+ to
                      imputed age, (2) estimated age at A+ to estimated age at
                      symptom onset, and (3) variance in cognitive performance
                      explained.Mean error between imputed and SILA-estimated age
                      at A+ (N = 26) was 1.15 years. Age at A+ explained $39\%$ of
                      estimated years to symptom onset (EYO) variance. Time from
                      A+ explained $19\%$ of cognitive composite variance and
                      $14\%$ of Clinical Dementia Rating Sum of Boxes CDR-SB
                      variance; EYO explained $43\%$ and $57\%,$ respectively.SILA
                      estimates A+ age in ADAD with reasonably good accuracy.
                      SILA-estimated time from A+ describes the start of
                      pathology, but the time from A+ onset to symptoms is
                      variable in ADAD and better described by EYO.Amyloid
                      chronicity predicts a 14-year preclinical AD phase in ADAD.
                      SILA accurately estimates age at A+ (MAE < 2 years). EYO
                      outperforms chronicity in predicting symptom onset. APP
                      mutation carriers show atypical amyloid accumulation.
                      Chronicity models help reveal AD heterogeneity in
                      preclinical stages.},
      keywords     = {Humans / Alzheimer Disease: genetics / Alzheimer Disease:
                      diagnostic imaging / Alzheimer Disease: pathology /
                      Alzheimer Disease: metabolism / Male / Female /
                      Positron-Emission Tomography / Middle Aged / Age of Onset /
                      Longitudinal Studies / Aged / Biomarkers / Disease
                      Progression / Amyloid: metabolism / Amyloid beta-Peptides:
                      metabolism / Alzheimer's disease (Other) / biomarkers
                      (Other) / genetic causes of Alzheimer's disease (Other) /
                      numeric methods (Other) / Biomarkers (NLM Chemicals) /
                      Amyloid (NLM Chemicals) / Amyloid beta-Peptides (NLM
                      Chemicals)},
      cin          = {AG Jucker},
      ddc          = {610},
      cid          = {I:(DE-2719)1210001},
      pnm          = {352 - Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41137622},
      doi          = {10.1002/alz.70812},
      url          = {https://pub.dzne.de/record/281816},
}